BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon 2012;12:e6151. [PMID: 23087759 DOI: 10.5812/hepatmon.6151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis. Exp Ther Med 2018;16:971-8. [PMID: 30116347 DOI: 10.3892/etm.2018.6255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
2 Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 2015; 21(38): 10790-10810 [PMID: 26478671 DOI: 10.3748/wjg.v21.i38.10790] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
3 Vosoghinia H, Esmaeilzadeh A, Ganji A, Hosseini SM, Jamehdar SA, Salehi M, Bahari A, Ghanaei O, Sahebari M, Rajabzadeh F, Ghaffarzadehgan K, Goshayeshi L. Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial. Razavi Int J Med 2016;4. [DOI: 10.17795/rijm36632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Hajiaghamohammadi A, Samimi R, Miroliaee A, Kazemifar AM, Nazem M. Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients. Glob J Health Sci 2014;7:75-81. [PMID: 25948447 DOI: 10.5539/gjhs.v7n3p75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ebrahimi Daryani N, Alavian SM, Somi MH, Torabi-nami M. Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013. Hepat Mon 2013;13. [DOI: 10.5812/hepatmon.16082] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sargolzaee Aval F, Behnaz N, Raoufy MR, Alavian SM. Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepat Mon 2014;14:e17028. [PMID: 24976838 DOI: 10.5812/hepatmon.17028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
7 Sadeghi F, Salehi-Vaziri M, Almasi-Hashiani A, Gholami-Fesharaki M, Pakzad R, Alavian SM. Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis. Hepat Mon. 2016;16:e35558. [PMID: 27274353 DOI: 10.5812/hepatmon.35558] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
8 Helal TEA, Radwan NA, Mahmoud HA, Zaki AM, Ahmed NS, Wahib AA, Aref AM. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4. Afr Health Sci 2019;19:1411-21. [PMID: 31148968 DOI: 10.4314/ahs.v19i1.14] [Reference Citation Analysis]
9 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
10 Ravi S, Nasiri Toosi M, Karimzadeh I, Ahadi-Barzoki M, Khalili H. Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran. Hepat Mon 2013;13:e11038. [PMID: 24032043 DOI: 10.5812/hepatmon.11038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
11 Ramezani A, Baesi K, Banifazl M, Mohraz M, Khorvash F, Yaran M, Tabarsi P, Dalirrooyfard AH, Motevalli F, Bavand A, Aghakhani A. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population. Clin Res Hepatol Gastroenterol 2019;43:594-602. [PMID: 31080115 DOI: 10.1016/j.clinre.2019.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Abbasinazari M, Behnava B, Panahi Y, Hajhossein Talasaz A, Salimi S, Keshvari M, Mehrnoush L, Karim Elizee P, Gholami Fesharaki M, Asgharinia M, Alavian SM. Plasma zinc level in hepatitis C patients with or without Beta thalassemia major; is there any difference? Hepat Mon 2013;13:e11138. [PMID: 24130600 DOI: 10.5812/hepatmon.11138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Butt N, Reema S, Ali Khan M, Abbasi A, Butt S, Khoso MM, Akbar A, Haleem F, Mahesar GB, Fahad A, Qureshi T. Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus 2019;11:e4458. [PMID: 31205844 DOI: 10.7759/cureus.4458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Jalilian S, Latifi SM, Makvandi M, Teimoori A, Azaran A, Parsanahad M, Kayedani G. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection. Indian J Med Microbiol 2017;35:262-8. [PMID: 28681817 DOI: 10.4103/ijmm.IJMM_16_309] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Haj-sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 2015; 21(29): 8935-8942 [PMID: 26269684 DOI: 10.3748/wjg.v21.i29.8935] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
16 Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S, Vahabpour R, Keyvani H. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol. 2014;86:1499-1506. [PMID: 24889558 DOI: 10.1002/jmv.23985] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
17 Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2015;15:e30780. [PMID: 26504470 DOI: 10.5812/hepatmon.30780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
18 Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, Jamnani FR, Fateh A, Siadat SD. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol 2017;162:181-9. [DOI: 10.1007/s00705-016-3095-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Bokharaei-salim F, Keyvani H, Salehi-vaziri M, Sadeghi F, Monavari SH, Mehrnoush L, Alavian SM. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients. Arch Virol 2014;159:2893-9. [DOI: 10.1007/s00705-014-2133-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]